# Martina Seiffert

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 89 papers | 3,905 citations | 147566 31 h-index | 128067 60 g-index |
| 95 all docs | 95 docs citations | 95 times ranked | 5998 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy. Haematologica, 2022, 107, 604-614. | 1.7 | 11 |
| 2 | Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. Blood, 2022, 139, 859-875. | 0.6 | 16 |
| 3 | Editorial: New Insights into the Complexity of Tumor Immunology in B-cell Malignancies: Tumor Immunology and Immunotherapy. Frontiers in Oncology, 2022, 12, 853620. | 1.3 | 0 |
| 4 | Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. Haematologica, 2021, 106, 968-977. | 1.7 | 26 |
| 5 | EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. Leukemia, 2021, 35, 2311-2324. | 3.3 | 27 |
| 6 | Proteomic and bioinformatic profiling of neutrophils in CLL reveals functional defects that predispose to bacterial infections. Blood Advances, 2021, 5, 1259-1272. | 2.5 | 6 |
| 7 | EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia. Leukemia, 2021, 35, 3152-3162. | 3.3 | 26 |
| 8 | IDO1-Targeted Therapy Does Not Control Disease Development in the EÂµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 1899. | 1.7 | 9 |
| 9 | Increased Bâ€cell activity with consumption of activated monocytes in severe COVIDâ€19 patients. European Journal of Immunology, 2021, 51, 1449-1460. | 1.6 | 10 |
| 10 | TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood, 2021, 137, 3064-3078. | 0.6 | 20 |
| 11 | Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients. Leukemia, 2021, , . | 3.3 | 3 |
| 12 | An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies. Blood Advances, 2021, 5, 5060-5071. | 2.5 | 9 |
| 13 | Antibody Peptides as Cancer Vaccineâ€"Turning Weapons to Targets. Clinical Cancer Research, 2021, 27, 659-661. | 3.2 | 1 |
| 14 | Editorial: New Insights Into the Complexity of Tumor Immunology in B-Cell Malignancies: Prognostic and Predictive Biomarkers and Therapy. Frontiers in Oncology, 2021, 11, 841763. | 1.3 | 0 |
| 15 | Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ TÂcell population that sustains anti-tumor immunity. Immunity, 2021, 54, 2825-2841.e10. | 6.6 | 57 |
| 16 | Editorial: New Insights Into the Complexity of Tumor Immunology in B-Cell Malignancies: Disease Biology and Signaling. Frontiers in Oncology, 2021, 11, 820984. | 1.3 | 0 |
| 17 | Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. Leukemia, 2020, 34, 100-114. | 3.3 | 31 |
| 18 | CD8<sup>+</sup> T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion. Leukemia and Lymphoma, 2020, 61, 351-356. | 0.6 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | TBETâ€expressing Th1 CD4<sup>+</sup>T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in EÂµâ€TCL1 mice. British Journal of Haematology, 2020, 189, 133-145. | 1.2 | 11 |
| 20 | IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell, 2020, 182, 1252-1270.e34. | 13.5 | 259 |
| 21 | Optimized Protocol for Isolation of Small Extracellular Vesicles from Human and Murine Lymphoid Tissues. International Journal of Molecular Sciences, 2020, 21, 5586. | 1.8 | 16 |
| 22 | T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?. Leukemia, 2020, 34, 2012-2024. | 3.3 | 70 |
| 23 | Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. Nature Cell Biology, 2020, 22, 896-906. | 4.6 | 93 |
| 24 | Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL. Genome Medicine, 2020, 12, 29. | 3.6 | 15 |
| 25 | HIF-1Î±: a potential treatment target in chronic lymphocytic leukemia. Haematologica, 2020, 105, 856-858. | 1.7 | 5 |
| 26 | Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?. Frontiers in Immunology, 2020, 11, 595818. | 2.2 | 13 |
| 27 | Immune Suppression in CLL Is Mediated By the L-Amino Acid Oxidase IL4I1, a Reason for the Treatment Failure of IDO1 Inhibitors. Blood, 2020, 136, 34-34. | 0.6 | 0 |
| 28 | Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia. Cancers, 2019, 11, 822. | 1.7 | 5 |
| 29 | IGF1R as druggable target mediating PI3K-Î´ inhibitor resistance in a murine model of chronic lymphocytic leukemia. Blood, 2019, 134, 534-547. | 0.6 | 51 |
| 30 | PI3KÎ´ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Leukemia, 2019, 33, 1427-1438. | 3.3 | 51 |
| 31 | Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. International Journal of Cancer, 2019, 144, 2762-2773. | 2.3 | 8 |
| 32 | Rejection of adoptively transferred EÂµ-TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines. Leukemia, 2019, 33, 1514-1539. | 3.3 | 12 |
| 33 | Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia, 2019, 33, 625-637. | 3.3 | 55 |
| 34 | Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia. Molecular Immunology, 2019, 110, 77-87. | 1.0 | 24 |
| 35 | Eomes and IL-10 Regulate Anti-Tumor Activity of T Cells in Chronic Lymphocytic Leukemia. Blood, 2019, 134, 4288-4288. | 0.6 | 0 |
| 36 | Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. Haematologica, 2018, 103, 688-697. | 1.7 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Checkpoint inhibition in the bone marrow. Nature Biomedical Engineering, 2018, 2, 793-794. | 11.6 | 2 |
| 38 | Autoantigen-Harboring Apoptotic Cells Hijack the Coinhibitory Pathway of T Cell Activation. Scientific Reports, 2018, 8, 10533. | 1.6 | 5 |
| 39 | CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia. Journal of Clinical Investigation, 2018, 128, 5465-5478. | 3.9 | 37 |
| 40 | Abstract LB-083: Targeting IRAK4 disrupts inflammatory pathways and tumor microenvironment in chronic lymphocytic leukemia regardless MYD88 mutational status. , 2018, , . | | 0 |
| 41 | Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 2650-2650. | 0.6 | 0 |
| 42 | Branchedâ€chain ketoacids secreted by glioblastoma cells via <scp>MCT</scp> 1 modulate macrophage phenotype. EMBO Reports, 2017, 18, 2172-2185. | 2.0 | 74 |
| 43 | Tumor-derived exosomes modulate PD-L1 expression in monocytes. Science Immunology, 2017, 2, . | 5.6 | 236 |
| 44 | BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood, 2016, 127, 2847-2855. | 0.6 | 100 |
| 45 | Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia, 2016, 30, 570-579. | 3.3 | 102 |
| 46 | CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model. Leukemia, 2016, 30, 1409-1413. | 3.3 | 15 |
| 47 | CLL Exosome-Derived Y RNA hY4 Induces TLR7/8-Mediated Inflammation and PD-L1 Expression in Monocytes. Blood, 2016, 128, 3217-3217. | 0.6 | 1 |
| 48 | Abstract A30: Chronic lymphocytic leukemia-derived extracellular vesicles mediate NFkB signaling and pro-inflammatory cytokine release in monocytes. , 2016, , . | | 0 |
| 49 | Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood, 2015, 126, 1106-1117. | 0.6 | 399 |
| 50 | PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood, 2015, 126, 203-211. | 0.6 | 158 |
| 51 | Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton. Leukemia, 2014, 28, 1289-1298. | 3.3 | 59 |
| 52 | Isolation, Structural Analyses and Biological Activity Assays against Chronic Lymphocytic Leukemia of Two Novel Cytochalasins â€" Sclerotionigrin A and B. Molecules, 2014, 19, 9786-9797. | 1.7 | 11 |
| 53 | Lenalidomide, an antiproliferative CLL drug. Blood, 2014, 124, 1545-1546. | 0.6 | 6 |
| 54 | Chronic Lymphocytic Leukemia-Exosomes Switch Endothelial and Mesenchymal Stromal Cells into Cancer-Associated Fibroblasts to Sustain Leukemic Cell Survival. Blood, 2014, 124, 2927-2927. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Abstract 5557: Systematic mapping of drug sensitivity in hematological malignancies identifies vulnerability of chronic lymphocytic leukemia with mutant p53. , 2014, , . | | 0 |
| 56 | Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model. Blood, 2014, 124, 3298-3298. | 0.6 | 0 |
| 57 | Chronic Lymphocytic Leukemia-Derived Extracellular Vesicles Contain a Distinctive Proteome, As Well As Specific Micro RNAs and Y RNAs. Blood, 2014, 124, 1968-1968. | 0.6 | 28 |
| 58 | The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in EÂµ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling. Blood, 2014, 124, 1966-1966. | 0.6 | 0 |
| 59 | Immune Checkpoint Blockade with Anti-PD-L1 Prevents Immune Dysfuntion and CLL Development in the TCL1 Adoptive Transfer Mouse Model. Blood, 2014, 124, 717-717. | 0.6 | 0 |
| 60 | Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. Blood, 2013, 121, 2503-2511. | 0.6 | 41 |
| 61 | Extracellular vesicles in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1826-1830. | 0.6 | 15 |
| 62 | Genome-wide identification of translationally inhibited and degraded miR-155 targets using RNA-interacting protein-IP. RNA Biology, 2013, 10, 1017-1029. | 1.5 | 33 |
| 63 | Bio-Activity and Dereplication-Based Discovery of Ophiobolins and Other Fungal Secondary Metabolites Targeting Leukemia Cells. Molecules, 2013, 18, 14629-14650. | 1.7 | 41 |
| 64 | Systematic Mapping Of Drug and Pathway Sensitivity In Chronic Lymphocytic Leukemia Identifies Synthetic Lethal Interactions Of Mutant p53. Blood, 2013, 122, 173-173. | 0.6 | 0 |
| 65 | Microenvironmental Factors and The Role Of Tumor Necrosis Factor Receptor Type 1 (TNFR-1) In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 4149-4149. | 0.6 | 0 |
| 66 | Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 1023-1031. | 0.6 | 34 |
| 67 | miRNA-130a Targets <i>ATG2B</i> and <i>DICER1</i> to Inhibit Autophagy and Trigger Killing of Chronic Lymphocytic Leukemia Cells. Cancer Research, 2012, 72, 1763-1772. | 0.4 | 185 |
| 68 | Fungal natural products targeting chronic lymphocytic leukemia. Planta Medica, 2012, 78, . | 0.7 | 0 |
| 69 | Lenalidomide Reduces Survival of Chronic Lymphocytic Leukemia Cells in Primary Co-Cultures by Altering the Myeloid Microenvironment. Blood, 2012, 120, 3894-3894. | 0.6 | 0 |
| 70 | Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica, 2011, 96, 408-416. | 1.7 | 80 |
| 71 | Antiapoptotic function of charged multivesicular body protein 5: A potentially relevant gene in acute myeloid leukemia. International Journal of Cancer, 2011, 128, 2865-2871. | 2.3 | 13 |
| 72 | MicroRNA-130a Targets ATG2B, AGO4 and DICER1, Inhibits Autophagy and Induces Cell Death in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1768-1768. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | The Toll-Like Receptor-Like Molecule CD180 and Soluble CD14 Transmit Survival Signals in B-Cell Chronic Lymphocytic Leukemia Cells Presumably by Acting As Co-Receptors,. Blood, 2011, 118, 3883-3883. | 0.6 | 0 |
| 74 | Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood, 2010, 116, 4223-4230. | 0.6 | 60 |
| 75 | Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia. Leukemia, 2009, 23, 2018-2026. | 3.3 | 40 |
| 76 | Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia, 2007, 21, 1977-1983. | 3.3 | 71 |
| 77 | Gab3 -Deficient Mice Exhibit Normal Development and Hematopoiesis and Are Immunocompetent. Molecular and Cellular Biology, 2003, 23, 2415-2424. | 1.1 | 48 |
| 78 | Gab3, a New DOS/Gab Family Member, Facilitates Macrophage Differentiation. Molecular and Cellular Biology, 2002, 22, 231-244. | 1.1 | 81 |
| 79 | The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. Blood, 2001, 97, 3303-3305. | 0.6 | 134 |
| 80 | Signal-regulatory protein Î± (SIRPÎ±) but not SIRPÎ² is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34+CD38â^'hematopoietic cells. Blood, 2001, 97, 2741-2749. | 0.6 | 164 |
| 81 | Cutting Edge: Signal-Regulatory Protein Î²1 Is a DAP12-Associated Activating Receptor Expressed in Myeloid Cells. Journal of Immunology, 2000, 164, 9-12. | 0.4 | 158 |
| 82 | Characterization and functional analysis of laminin isoforms in human bone marrow. Blood, 2000, 96, 4194-4203. | 0.6 | 5 |
| 83 | Human Signal-Regulatory Protein Is Expressed on Normal, But Not on Subsets of Leukemic Myeloid Cells and Mediates Cellular Adhesion Involving Its Counterreceptor CD47. Blood, 1999, 94, 3633-3643. | 0.6 | 259 |
| 84 | AC133 Antigen Expression Is Not Restricted to Acute Myeloid Leukemia Blasts But Is Also Found on Acute Lymphoid Leukemia Blasts and on a Subset of CD34+ B-Cell Precursors. Blood, 1999, 94, 832-833. | 0.6 | 75 |
| 85 | Expression of Novel Surface Antigens on Early Hematopoietic Cellsa. Annals of the New York Academy of Sciences, 1999, 872, 25-39. | 1.8 | 60 |
| 86 | Human Signal-Regulatory Protein Is Expressed on Normal, But Not on Subsets of Leukemic Myeloid Cells and Mediates Cellular Adhesion Involving Its Counterreceptor CD47. Blood, 1999, 94, 3633-3643. | 0.6 | 36 |
| 87 | AC133 Antigen Expression Is Not Restricted to Acute Myeloid Leukemia Blasts But Is Also Found on Acute Lymphoid Leukemia Blasts and on a Subset of CD34+ B-Cell Precursors. Blood, 1999, 94, 832-833. | 0.6 | 2 |
| 88 | Mitogenic and adhesive effects of tenascin-C on human hematopoietic cells are mediated by various functional domains. Matrix Biology, 1998, 17, 47-63. | 1.5 | 47 |
| 89 | Clonal Evolution in Chronic Lymphocytic Leukemia is Scant in Relapsed But Accelerated in Refractory Cases. SSRN Electronic Journal, 0, , . | 0.4 | 0 |